Companies
- Companies
- Company details
Cellerix S.L.
Out-licensing
Phase II Clinical Development of Cx501: Chimeric Skin for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) More
Phase II Clinical Development of Cx601 for the Treatment of Fistulas: Expanded Allogeneic Adipose Derived Stem Cells for Local Delivery More
Phase III Clinical Development of Cx 401 for the Treatment of Complex Perianal Fistulas More
Preclinical Development of Cx611 for the Treatment of Autoimmune and Inflammatory Diseases: Expanded Allogeneic Adipose Derived Stem Cells for Local Delivery More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 38 pages - $500
Nov 2010 - 44 pages - $600
Jul 2010 - 21 pages - $750
May 2011 - 39 pages - $500
Mar 2011 - 42 pages - $1,000
Apr 2011 - 33 pages - $500
Aug 2011 - 34 pages - $500
Dec 2010 - 46 pages - $500
Jul 2011 - 137 pages - $2,350
Aug 2008 - 127 pages - $2,350
Contact details
Head office
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us